Partially — 1 of 3 ingredients has pharmacogenetic evidence.
Relevant genes: CYP1A2
Used for: Tension headaches (often prescribed for chronic daily headache)Fioricet is a prescription combination of butalbital (a short-acting barbiturate), acetaminophen, and caffeine. Only one of those ingredients has an established pharmacogenetic profile: caffeine, which is cleared by CYP1A2. If you're a rapid CYP1A2 metabolizer, the caffeine wears off faster than the butalbital and acetaminophen, which can change the character of the headache relief (especially for the first hour or two when caffeine's vasoconstrictive effect is doing real analgesic work). If you're a slow metabolizer, the caffeine sticks around much longer than the other components, which is part of why some patients report jitteriness or evening insomnia from a morning Fioricet dose.
Butalbital is a short-acting barbiturate that is metabolized primarily by CYP3A4 with minor contributions from CYP2C9. Neither pathway has clinically actionable pharmacogenetic variants that would justify dose adjustment. Butalbital does have well-known non-genetic risks (tolerance, rebound headache with frequent use, dependence), but those aren't a pharmacogenetic story.
Acetaminophen clears through UGT and sulfate conjugation. No clinical guideline currently recommends dose adjustment based on genetics. Large variations in acetaminophen response across individuals are driven more by liver health, alcohol use, and concurrent medications than by inherited variants.
Caffeine is metabolized almost exclusively by CYP1A2. In Fioricet, it's doing two jobs: potentiating the acetaminophen analgesic effect, and providing vasoconstriction that helps with vascular headache components. Rapid metabolizers lose that second effect quickly; slow metabolizers may feel the caffeine well into the evening.
Read the full caffeine genetics guide →Published guidance from Gene2Rx on how caffeine should be dosed or substituted based on your CYP1A2 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
|
Ultrarapid Metabolizer
CYP1A2
|
You clear caffeine very quickly, so you may need more or more frequent servings to feel its effects. |
Gene2Rx
Caffeine is cleared very quickly, which may reduce its stimulant effect. You may require larger or more frequent servings to achieve your desired level of stimulation. Monitor your intake to avoid excessive consumption.
|
Moderate |
|
Rapid Metabolizer
CYP1A2
|
You clear caffeine quickly, so you might drink more coffee to feel its effects. |
Gene2Rx
You clear caffeine faster than average, which may shorten its duration of action. You may need more frequent servings to maintain the desired effect. Space your servings to prevent withdrawal symptoms.
|
Moderate |
|
Normal Metabolizer
CYP1A2
|
You clear caffeine at a normal rate; usual intake guidelines apply. |
Gene2Rx
Follow standard moderate intake guidelines (≤400 mg/day).
|
— |
|
Intermediate Metabolizer
CYP1A2
|
You clear caffeine more slowly, so effects last longer—avoid drinking coffee late in the day. |
Gene2Rx
Standard advice on moderate caffeine intake; consider avoiding late-day caffeine to prevent sleep disturbances.
|
— |
|
Slow Metabolizer
CYP1A2
|
You clear caffeine slowly, so it stays in your system longer—consider drinking less coffee to avoid jitters or poor sleep. |
Gene2Rx
Recommend reduced intake (e.g. ≤100 mg/day) and longer intervals between doses to avoid adverse effects.
|
Moderate |
|
Indeterminate
CYP1A2
|
We don’t know how your genetics affect caffeine metabolism. |
Gene2Rx
Follow general caffeine guidelines and monitor personal tolerance.
|
— |
|
Not available
CYP1A2
|
We don’t know how your genetics affect caffeine metabolism. |
Gene2Rx
Follow general caffeine guidelines and monitor personal tolerance.
|
— |
Source: Gene2Rx
CYP1A2 is the liver enzyme that clears caffeine, clozapine, and a handful of other drugs. Its activity is shaped by both genetics and lifestyle (smoking speeds it up, certain foods slow it down), but the underlying gene still sets your baseline. About 40 percent of people carry a variant that classifies them as rapid metabolizers; the rest process caffeine at an average or slower rate.
Rapid metabolizers clear caffeine quickly and may feel less effect from a given dose. Slower metabolizers feel caffeine longer and at lower doses.
Fioricet is not a drug where pharmacogenetic testing is going to dramatically change treatment. The bigger clinical concerns with Fioricet are rebound headache from frequent use and the tolerance profile of butalbital. That said, if you take Fioricet and notice that caffeine-related side effects (jitters, insomnia) feel unusually strong or unusually absent, your CYP1A2 phenotype is a reasonable explanation, and it's the same phenotype that affects any other caffeine-containing medication you take.
Yes. The version that adds codeine (usually called Fioricet #3 or Fioricet with codeine) introduces a second pharmacogenetic dimension, because codeine activation depends on CYP2D6. Poor CYP2D6 metabolizers get essentially no analgesic effect from the codeine portion. If you're specifically asking about the codeine version, look up Tylenol #3 for the CYP2D6 story.
Caffeine is genuinely analgesic-enhancing in tension and vascular headaches. It narrows blood vessels in the brain and potentiates the effect of non-opioid analgesics like acetaminophen. It's not a stimulant added for wakefulness; it's part of the analgesic mechanism.
Not directly. Butalbital clearance runs through CYP3A4, not CYP1A2. The dependence and rebound headache risks with Fioricet are behavioral and pharmacological, not pharmacogenetic. The best tool for that risk is frequency of use, not a genetic test.
This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.
Get your report Look up another medicationInformational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.